Predict your next investment

Corporate Venture
pfizer.com/partners/venture-investments

See what CB Insights has to offer

Investments

176

Portfolio Exits

44

Funds

1

Partners & Customers

1

About Pfizer Venture Investments

Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, Strategy, and Innovation division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline.

Pfizer Venture Investments Headquarter Location

235 East 42nd Street

New York, New York, 10017,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pfizer Venture Investments

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Pfizer Venture Investments in 1 Expert Collection, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Research containing Pfizer Venture Investments

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Pfizer Venture Investments in 1 CB Insights research brief, most recently on Jan 19, 2021.

Latest Pfizer Venture Investments News

DEM BioPharma Launches with $70 Million Financing

Jun 27, 2022

Company will pursue untapped opportunities in the field of innate immune system checkpoints to eliminate cancer Proprietary platform leverages CRISPR screening and macrophage biology to systematically discover and drug “don’t eat me” (DEM) and “eat me” (EM) signals June 23, 2022 06:00 AM Eastern Daylight Time DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells and macrophages. The company’s approach builds on the groundbreaking research from its scientific co-founders: Jonathan Weissman, Ph.D. - Whitehead Institute, National Academy of Sciences member, HHMI, world leader in genome-wide CRISPR screens; Michael Bassik, Ph.D. - Stanford University, a distinguished biologist in cancer, phagocytes, and CRISPR screening; and Kipp Weiskopf, M.D., Ph.D. – Whitehead Fellow and physician at Dana-Farber Cancer Institute, one of the world’s leaders in macrophage and cancer biology. DEM Bio is focused on accessing the largely untapped opportunity around macrophage biology and innate immune system pathways to discover potent DEM and EM signals on cancers and expand the therapeutic potential of the field beyond the relatively small number of signals targeted by current investigational therapies. The company’s proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. DEM Bio also announced the appointment of Jan Skvarka, former CEO of Trillium Therapeutics (acquired by Pfizer for $2.22 billion in November 2021), as Executive Chairman. As part of the financing, Christoph Westphal, M.D., Ph.D., Founding CEO, DEM Bio, and Founding Partner Longwood Fund; Dan Janney, Managing Partner, Alta Partners; Dylan Morris, Managing Director, Insight Partners; Marie-Claire Peakman, Ph.D., Principal, Pfizer Ventures; and Hiro Kimura, Ph.D., Investment Director, Astellas Venture Management have joined DEM Bio’s Board of Directors . “Currently known DEM signals have been described in an ad hoc manner. DEM Bio’s founders discovered a scalable approach to systematically unlock the potential of innate immune system checkpoints,” noted Dr. Westphal. “This financing from an exceptional group of investors positions us to execute on our ambitious plans to develop the next generation of macrophage checkpoint inhibitors that may revolutionize how we treat cancer,” said Mr. Skvarka. DEM Bio has assembled a world-class Scientific Advisory Board consisting of leaders in the field of CRISPR high-throughput screening, immune phagocytes, cancer biology, and therapeutic development, including co-founders Drs. Weissman, Bassik and Weiskopf, Roarke Kamber, Ph.D., Postdoctoral fellow, Genetics, Stanford School of Medicine, Dian Yang, Ph.D., Postdoctoral fellow, Whitehead Institute for Biomedical Research, as well as Kai Wucherpfennig, M.D., Ph.D., Professor and Chair, Dana-Farber Cancer Institute; Dane Wittrup, Ph.D., Professor of Chemical Engineering & Bioengineering, MIT; and Bob Uger, Ph.D., former CSO, Trillium Therapeutics. “The currently known DEM and EM pathways were discovered serendipitously,” said Dr. Bassik. “Similar to other areas of immunotherapy, there are likely other signals that are more potent and offer better therapeutic targets, but no one has yet taken a systematic approach to identifying those pathways.” “By leveraging cutting-edge functional genomics and macrophage biology, we created the CHoMP platform to discover new DEM/EM signals in a fully unbiased and systematic way,” said Dr. Weiskopf. “CHoMP is a highly differentiated platform built on unique, proprietary CRISPR screening capabilities in primary human cells, enabling DEM Bio to methodically evaluate unexplored DEM/EM signals,” said Dr. Weissman. The CHoMP platform has identified a number of promising new DEM/EM signals, including the novel DEM pathway APMAP. In preclinical work, targeting APMAP enhanced tumor cell phagocytosis in multiple cancer cell types and animal cancer models, and demonstrated synergistic effects with a broad range of tumor-binding antibodies. David Donabedian, Co-founder and start-up CEO of DEM Bio, and Operating Partner, Longwood Fund added, “APMAP is just one of the promising programs identified using the CHoMP platform, and the encouraging initial data on this pathway has helped validate our differentiated approach to identifying novel, potent DEM/EM signals. The company plans to use proceeds from this financing to further develop our platform and to advance our portfolio of novel targets towards therapeutic development in oncology.” About DEM BioPharma Inc. DEM Bio is pioneering the next generation of immunotherapeutics that unleash the innate immune system to eliminate tumors by targeting ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells, macrophages and other myeloid effector cells. Founded by Longwood Fund, the company’s approach builds on the groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders: Drs. Jonathan Weissman and Kipp Weiskopf of the Whitehead Institute and Dr. Michael Bassik of Stanford University. The proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) utilizes CRISPR-based functional genomic screens in human cancer cells and/or primary macrophages to discover and validate new DEM and EM signals that could profoundly induce and enhance cancer cell elimination through increased phagocytosis. Contacts

Pfizer Venture Investments Investments

176 Investments

Pfizer Venture Investments has made 176 investments. Their latest investment was in DEM BioPharma as part of their Series A on June 6, 2022.

CBI Logo

Pfizer Venture Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/23/2022

Series A

DEM BioPharma

$70M

Yes

3

6/13/2022

Series C

ImCheck Therapeutics

$103M

No

4

6/7/2022

Series B

ImmunOs Therapeutics

$74M

No

4

3/10/2022

Series E

Subscribe to see more

$99M

Subscribe to see more

10

3/8/2022

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/23/2022

6/13/2022

6/7/2022

3/10/2022

3/8/2022

Round

Series A

Series C

Series B

Series E

Series A - II

Company

DEM BioPharma

ImCheck Therapeutics

ImmunOs Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$70M

$103M

$74M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

4

4

10

10

Pfizer Venture Investments Portfolio Exits

44 Portfolio Exits

Pfizer Venture Investments has 44 portfolio exits. Their latest portfolio exit was Pyxis Oncology on October 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/8/2021

IPO

$99M

Public

9

7/20/2021

Acq - Fin

$99M

1

6/15/2021

Acquired

$99M

1

5/28/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/27/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/8/2021

7/20/2021

6/15/2021

5/28/2021

5/27/2021

Exit

IPO

Acq - Fin

Acquired

Acquired

Acq - Pending

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

9

1

1

10

10

Pfizer Venture Investments Acquisitions

1 Acquisition

Pfizer Venture Investments acquired 1 company. Their latest acquisition was Saama Technologies on October 20, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/20/2021

Debt

$99M

$79.25M

Acq - Fin

14

Date

10/20/2021

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$79.25M

Note

Acq - Fin

Sources

14

Pfizer Venture Investments Fund History

1 Fund History

Pfizer Venture Investments has 1 fund, including Pfizer Venture Investments.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/6/2018

Pfizer Venture Investments

$600M

2

Closing Date

6/6/2018

Fund

Pfizer Venture Investments

Fund Type

Status

Amount

$600M

Sources

2

Pfizer Venture Investments Partners & Customers

1 Partners and customers

Pfizer Venture Investments has 1 strategic partners and customers. Pfizer Venture Investments recently partnered with Nodality on August 8, 2012.

Date

Type

Business Partner

Country

News Snippet

Sources

8/9/2012

Partner

United States

South San Francisco, California, August 9, 2012. Nodality :: Company :: News and Resources :: Press Releases / Company News Nodality Enters into a Multi-Year Strategic Collaboration with Pfizer in Autoimmune Disease.

Jose-Carlos Gutierrez-Ramos , Senior Vice President , BioTherapeutics R&D at Pfizer Venture Investments said , Our partnership with Nodality , Inc. exemplifies Pfizer Venture Investments 's commitment to Precision Medicine by providing us with earlier insight into a compound 's potential clinical profile , which can help reduce attrition rates , accelerate development and improve patient targeting .

2

Date

8/9/2012

Type

Partner

Business Partner

Country

United States

News Snippet

South San Francisco, California, August 9, 2012. Nodality :: Company :: News and Resources :: Press Releases / Company News Nodality Enters into a Multi-Year Strategic Collaboration with Pfizer in Autoimmune Disease.

Jose-Carlos Gutierrez-Ramos , Senior Vice President , BioTherapeutics R&D at Pfizer Venture Investments said , Our partnership with Nodality , Inc. exemplifies Pfizer Venture Investments 's commitment to Precision Medicine by providing us with earlier insight into a compound 's potential clinical profile , which can help reduce attrition rates , accelerate development and improve patient targeting .

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.